Enrolled patients were randomized to either switching to LdT ( @ mg/d orally ) plus ADV ( @ mg/d orally ) ( LdT + ADV group ) or to continuation with LAM ( @ mg/d orally ) plus ADV ( @ mg/d orally ) ( LAM + ADV group ) , and were followed for @ wk .